Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V H Brophy

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Immunogenetics|March 7, 1998
Expression of CD14 corrects the slow response to lipopolysaccharide in the 1B8 mutant of the B cell lymphoma 70Z/3V H Brophy, C H Sibley
Antimicrobial Agents and Chemotherapy|December 20, 2000
Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoaH Lau, J T Ferlan, V H Brophy, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiaeV H Brophy, J Vasquez, R G Nelson, et al.
Acta Neurologica Scandinavica|March 8, 2008
Genetic profile of ischemic cerebrovascular disease and carotid stenosisK Kostulas, V H Brophy, K Moraitis, et al.
American Journal of Human Genetics|May 4, 2001
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expressionV H Brophy, R L Jampsa, J B Clendenning, et al.
Pharmacogenetics|July 18, 2000
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotypeV H Brophy, G P Jarvik, R J Richter, et al.
Pharmacogenetics|February 24, 2001
Polymorphisms in the human paraoxonase (PON1) promoterV H Brophy, M D Hastings, J B Clendenning, et al.
Methods (San Diego, Calif.)|February 12, 1998
Yeast as a model system to study drugs effective against apicomplexan proteinsC H Sibley, V H Brophy, S Cheesman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2000
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotypeG P Jarvik, L S Rozek, V H Brophy, et al.
Neurotoxicology|October 7, 2000
The PON1 gene and detoxicationC E Furlong, W F Li, V H Brophy, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Immunogenetics|March 7, 1998
Expression of CD14 corrects the slow response to lipopolysaccharide in the 1B8 mutant of the B cell lymphoma 70Z/3V H Brophy, C H Sibley
Antimicrobial Agents and Chemotherapy|December 20, 2000
Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoaH Lau, J T Ferlan, V H Brophy, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerevisiaeV H Brophy, J Vasquez, R G Nelson, et al.
Acta Neurologica Scandinavica|March 8, 2008
Genetic profile of ischemic cerebrovascular disease and carotid stenosisK Kostulas, V H Brophy, K Moraitis, et al.
American Journal of Human Genetics|May 4, 2001
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expressionV H Brophy, R L Jampsa, J B Clendenning, et al.
Pharmacogenetics|July 18, 2000
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotypeV H Brophy, G P Jarvik, R J Richter, et al.
Pharmacogenetics|February 24, 2001
Polymorphisms in the human paraoxonase (PON1) promoterV H Brophy, M D Hastings, J B Clendenning, et al.
Methods (San Diego, Calif.)|February 12, 1998
Yeast as a model system to study drugs effective against apicomplexan proteinsC H Sibley, V H Brophy, S Cheesman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 14, 2000
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotypeG P Jarvik, L S Rozek, V H Brophy, et al.
Neurotoxicology|October 7, 2000
The PON1 gene and detoxicationC E Furlong, W F Li, V H Brophy, et al.
Pageof 2